AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04816721
Drug: EDP-938
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT06643260
Drug: piclidenoson
RxNorm normalized name: Piclidenoson
DrugBank: Piclidenoson (DB05511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piclidenoson is a selective A3AR agonist, supplied as tablets.
Trial: NCT05124951
Drug: Carboplatin/etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia germinoma
Trial: NCT05124951
Drug: Ifosfamide/cisplatin/etoposide
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide/cisplatin/etoposide regimen is applied as induction chemotherapy in patients with basal ganglia non-germinomatous germ cell tumors.
Trial: NCT05618925
Drug: N803
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nogapendekin alfa inbakicept (also known as ALT-803; recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex\])
Trial: NCT05618925
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-β-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase. The chemical name for fludarabine phosphate is 9H-Purin-6-amine, 2-fluoro-9-(5-0-phosphono β-D-arabino-furanosyl) (2-fluoro-ara-AMP). The molecular formula of fludarabine phosphate is C10H13FN5O7P and it has a molecular weight of 365.2.
Trial: NCT05618925
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD and has a binding affinity for the CD20 antigen of approximately 8.0 nM.
Trial: NCT05218434
Drug: AX-158
RxNorm normalized name: AX
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administrations of AX-158
Trial: NCT06613477
Drug: PK/PD Model Based Dosing of Digoxin in Infants with Single Ventricle Heart Disease
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Table 3: Digoxin dosing regimen based on optimized Cmin,ss Dose to be given twice daily (mcg/kg/dose) PNA\<30 days 30 days \< PNA \< 180 days eGFR≤40 1.4 1.4 40\<eGFR≤60 1.6 1.6 eGFR\>60 1.9 2.8
Trial: NCT06673654
Drug: Ruxolitinib Topical Cream 1.5%
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
Trial: NCT06673654
Drug: OPZELURA (Ruxolitinib) Cream
RxNorm normalized name: Opzelura
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigational product is to be self-administered by applying a thin layer twice daily to cover the affected areas up to 20% body surface area for approximately 8 weeks. The maximum weekly dose of the study drug should not exceed 60 g.
Trial: NCT06686641
Drug: Local and systemical treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Evaluating the management of the edema including topical/local treatment (dexamethasone and NSAID, periocular injections, and dexamethasone intravitreal implant) and systemic treatment (prednisolone, DMARD, and biological agents, for example TNF-alpha inhibitors and interleukin-6 inhibitors). Moreover, the duration of any treatment as well as numbers of injections or implants.
Trial: NCT06001749
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A tryptamine derivative, capsule, taken orally.
Trial: NCT05569187
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year
Trial: NCT05267600
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Prednisone
Trial: NCT05513573
Drug: HLX07
RxNorm normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg, D1，Q3W
Trial: NCT05513573
Drug: HLX10
RxNorm normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg, D1, up to 2 years,Q3W
Trial: NCT05179577
Drug: Arbaclofen
RxNorm normalized name: Arbaclofen
DrugBank: Arbaclofen (DB08891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbaclofen Extended Release Tablets
Trial: NCT06185751
Drug: Lymphodepleting chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cyclophosphamide 500 mg/m\^2 IV on Days -5, -4, and -3~* Fludarabine 30 mg/m\^2 IV on Days -5, -4, and -3
Trial: NCT06161220
Drug: Carbidopa capsule
RxNorm normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 4x 100 mg
Trial: NCT06161220
Drug: Moxifloxacin Tablets, USP
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 400 mg
Trial: NCT06168773
Drug: Haloperidol Injection
RxNorm normalized name: Haloperidol Injection
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: to evaluate the efficacy and safety of short-term intravenous combination of low-dose haloperidol and magnesium for delirium prevention in critically ill elderly patients after elective major surgery.
Trial: NCT05536791
Drug: Dabigatran Etexilate (DE)
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran Etexilate (DE)
Trial: NCT04835259
Drug: Selenium Amino Acid Chelate (Selenium ACE cream)
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: application of a topical agent over the whole face for 6 months
Trial: NCT06253650
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 cycles of: 5-fluorouracil 2600 mg/m2 continuous intravenous infusion day 1 for 24 hours every 2 weeks, leucovorin 200 mg/m2 intravenous infusion on day 1 every 2 weeks, oxaliplatin 85 mg/m2 intravenous infusion on day 1 every 2 weeks, and docetaxel 50 mg/m2 intravenous infusion on day 1 every 2 weeks.
Trial: NCT05609253
Drug: Itraconazole in capsule form
RxNorm normalized name: itraconazole Oral Capsule
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with high-risk BE will receive two weeks of itraconazole in the capsule form (N=5).
Trial: NCT05609253
Drug: Itraconazole in solution form
RxNorm normalized name: itraconazole Oral Solution
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with high-risk BE will receive two weeks of itraconazole in the solution form (N=5).
Trial: NCT05280054
Drug: AV-101
RxNorm normalized name: AV-101
DrugBank: AV-101 (DB12878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg capsules
Trial: NCT05280054
Drug: Probenecid
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg oral
Trial: NCT05470283
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05470283
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT05470283
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT05470283
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT05796765
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of 2.5 ml, 0.9% Sodium Chloride, USP
Trial: NCT05406401
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV or oral administration (per local guidelines)
Trial: NCT05176665
Drug: EMB-01
RxNorm normalized name: EMB-01
DrugBank: EMB-01 (DB16091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses).
Trial: NCT05689099
Drug: Semaglutide B, 1.34 mg/mL
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
Trial: NCT05689099
Drug: Semaglutide B, 0.68 mg/mL
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.
Trial: NCT06360055
Drug: Dabigatran Etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single oral dose of 110mg (low dose specification in the instructions) or lower of dabigatran etexilate on an empty stomach on the morning of day 1 and day 16 of the trial period.
Trial: NCT06082843
Drug: Avenciguat (BI 685509)
RxNorm normalized name: Avenciguat
DrugBank: Avenciguat (DB18882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avenciguat (BI 685509)
Trial: NCT05989997
Drug: 68Ga-NOTA-SNA002
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.
Trial: NCT06564935
Drug: Heptaminol Hydrochloride
RxNorm normalized name: heptaminol hydrochloride
DrugBank: Heptaminol (DB13574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heptaminol hydrochloride will be administrated in its solution form 4ml/kg. The mean dose used will be 25 drops = 150 mg and will be given 1.5 to 2 hours before spinal anesthesia
Trial: NCT01296204
Drug: BB4 antibody-Iodine 131
RxNorm normalized name: Iodine-131 anti-b1 antibody
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of an antibody after labelling with Iodine 131
Trial: NCT04392622
Drug: D-Limonene Gelcaps
RxNorm normalized name: D-(+)-limonene
DrugBank: (4R)-limonene (DB08921)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally at 2 to 8 grams daily
Trial: NCT04392622
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of Care -Cisplatin as 100 mg/m2 IV
Trial: NCT06560892
Drug: Bupivacaine injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients received intraperitoneal bupivacaine 50 ml 0.25% + 5 ml normal saline.
Trial: NCT06560892
Drug: Dexmedetomidine injection
RxNorm normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients were given intraperitoneal bupivacaine 50 ml 0.25% + dexmedetomidine 1 μg/kg with normal saline 5 ml.
Trial: NCT06563778
Drug: Chidamide; Decitabine; Anti-PD-1 Antibody
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
Trial: NCT06563778
Drug: Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab Vedotin 1.2-1.8mg/kg day 1, Bendamustine 70-90mg/m2 day1-2, Anti-PD-1 antibody day 2. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
Trial: NCT05360784
Drug: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
Trial: NCT05548296
Drug: ACR-368
RxNorm normalized name: ACR-16
DrugBank: ACR-16 (DB05371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACR-368 is an experimental drug
Trial: NCT05548296
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368
Trial: NCT06414031
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT05014919
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets
Trial: NCT04981912
Drug: HDMP + rituximab as a means of debulking prior to initiating venetoclax.
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Patients will receive HDMP + Rituximab for 1 cycle, followed by reassessment of Tumor Burden,~* If Tumor Burden classification is low after HDMP + Rituximab (lymph nodes \< 5cm in diameter AND absolute lymphocyte count \< 25k/uL), patients will initiate venetoclax dose ramp-up, with ramp-up schedule according to venetoclax package insert.~* Patients who still have a disease burden (lymphadenopathy \> 5 cm or ALC \> 25k/iL) that meets criteria for medium or high risk of TLS after 1 cycle of HDMP + Rituximab are given the option to repeat a 2nd cycle of HDMP + Rituximab prior to venetoclax dose ramp-up.
Trial: NCT04708847
Drug: GYM329
RxNorm normalized name: GYM329
DrugBank: GYM329 (DB18590)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GYM329 subcutaneous injection
Trial: NCT04849273
Drug: TPX-0131
RxNorm normalized name: TPX-4589
DrugBank: TPX-4589 (DB18604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TPX-0131 tablets
Trial: NCT06549231
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: one course of IV rituximab consisting of an infusion of 1000 mg rituximab (diluted in 500 mL of saline 0.9 % sodium chloride) will be given at day 1, day 15 and an infusion of 500 mg rituximab (in 500 mL of saline 0.9 % sodium chloride) at week 24;
Trial: NCT04724837
Drug: Zibotentan
RxNorm normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive zibotentan as per the arms they are randomized.
Trial: NCT04724837
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
Trial: NCT03763370
Drug: Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd)
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Belantamab mafodotin~•Belantamab mafodotin 2.5 milligram per kilogram (mg/kg) intravenous (IV) will be administered at every cycle, once every 3 Weeks, on Day 1 of every cycle, until completion of treatment.~Drug: Bortezomib •Bortezomib will be administered based on the full prescribing information, for the first 8 Cycles~Drug: Dexamethasone~•Dexamethasone will be administered based on the full prescribing information, for the first 8 Cycles
Trial: NCT03763370
Drug: Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug: Belantamab mafodotin:~* Cycle 1: Belantamab mafodotin 2.5 mg/kg IV administered once~* Cycle 2 onward: Belantamab mafodotin 1.9 mg/kg IV administered once every 4 weeks until completion of treatment~Drug: Pomalidomide •Pomalidomide will be administered at every cycle, based on the full prescribing information~Drug: Dexamethasone~•Dexamethasone will be administered at every cycle, based on the full prescribing information
Trial: NCT06120842
Drug: Bimatoprost Implant System (High Dose)
RxNorm normalized name: bimatoprost Drug Implant
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL
Trial: NCT06120842
Drug: Bimatoprost Implant System (Low Dose)
RxNorm normalized name: bimatoprost Drug Implant
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost Implant System (Low Dose) used in combination with the SpyGlass IOL
Trial: NCT06120842
Drug: Timolol Maleate Ophthalmic Solution, 0.5%
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol Maleate Ophthalmic Solution 0.5% BID
Trial: NCT05852340
Drug: Ritlecitinib
RxNorm normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)
Trial: NCT06484881
Drug: Topical minoxidil 5%
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical minoxidil 5%
Trial: NCT04344873
Drug: Abatacept 10 mg/kg
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept injection at day twenty eight and day forty two.
Trial: NCT05916937
Drug: omalizumab 300 mg every four weeks
RxNorm normalized name: omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12.
Trial: NCT05916937
Drug: omalizumab 300 mg every six weeks
RxNorm normalized name: omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12.
Trial: NCT05810597
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05645380
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC=6, IV
Trial: NCT05645380
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2, IV
Trial: NCT05645380
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg, IV
Trial: NCT05286619
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200mg will be administered on Day 1 every 3 weeks for up to 24months
Trial: NCT05286619
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin at 35 mg/m2 IV using a split dose regimen on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles.
Trial: NCT05286619
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin at AUC 5 IV on Day 1 of each 3-week cycle, up to 6 cycles.
Trial: NCT05286619
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1250mg/m2 IV on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles
Trial: NCT06570850
Drug: Colistin Sodium Methanesulfonate
RxNorm normalized name: Colistin methanesulfonic acid
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous colistin (colistinmethate soidum) 5 mg/kg/day intravenous (dosage will be adjusted according to creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
Trial: NCT06570850
Drug: Colistin Sodium Methanesulfonate plus Fosfomycin
RxNorm normalized name: Colistin methanesulfonic acid
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous colistin(dosage is same as colistin group) plus intravenous fosfomycin(dosage will be adjusted according to MIC and creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
Trial: NCT06108947
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin discontinuation
Trial: NCT05724069
Drug: Velusetrag
RxNorm normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.